Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 14/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467789 | 0.86 | NR3C1 (0.50) | SMONR3C1PGR | |
| SCHEMBL6281960 | 0.75 | CYP11B2 (0.59) | CYP11B2SMONR3C1CYP11B1 | |
| SCHEMBL836942 | 0.75 | NR3C1 (0.53) | CYP11B2NR3C1PGR | |
| SCHEMBL6185201 | 0.73 | CYP11B2 (0.59) | CYP11B2SMOMAPK8MAPK9MAPK10 | |
| SCHEMBL6209189 | 0.71 | CYP11B2 (0.53) | CYP11B2SMOMAPK8MAPK9MAPK10 | |
| SCHEMBL541362 | 0.70 | NR3C1 (0.54) | SMONR3C1PGR | |
| SCHEMBL4384679 | 0.69 | NR3C1 (0.57) | SMONR3C1PGR | |
| SCHEMBL15839046 | 0.68 | CYP11B2 (1.00) | CYP11B2SMONR3C1CYP11B1PGR | |
| SCHEMBL9943308 | 0.68 | NR3C1 (0.65) | SMONR3C1PGR | |
| SCHEMBL413192 | 0.68 | NR3C1 (0.45) | CYP11B2SMONR3C1CYP11B1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |